Stifel Financial
VRCA icon

Stifel Financial’s Verrica Pharmaceuticals VRCA Stock Holding History

Stifel Financial’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,391
Closed -$20.2K – 3490
2024
Q3 		$20.2K Sell
1,391
-344
-20% -$15.5K ﹤0.01% 3341
2024
Q2 		$126K Sell
1,735
-315
-15% -$24.2K ﹤0.01% 3180
2024
Q1 		$121K Hold
2,050
– – ﹤0.01% 3173
2023
Q4 		$150K Hold
2,050
– – ﹤0.01% 3107
2023
Q3 		$79.6K Buy
+2,050
New +$104K ﹤0.01% 3141
2023
Q1 		– Sell
-1,613
Closed -$44.3K – 3432
2022
Q4 		$44.3K Buy
+1,613
New +$43K ﹤0.01% 3198

Other funds holding VRCA

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SA
Sovran Advisors San Diego, California $1.34B AUM 21.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Stifel Financial's VRCA Position: Q4 2024 in Review

Stifel Financial sold out of Verrica Pharmaceuticals (VRCA) in Q4 2024, closing a stake of 1,391 shares — an estimated $20.2K sold.

Stifel Financial first reported a position in VRCA in Q4 2022 and held it in 6 quarters. The position peaked at $150K in Q4 2023. 81 funds tracked by Wall St. Rank hold VRCA as of Q4 2024.

  • Stifel Financial reported no remaining Verrica Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Stifel Financial sold 1,391 Verrica Pharmaceuticals shares in Q4 2024, an estimated $20.2K.
  • Stifel Financial first reported a position in Verrica Pharmaceuticals in Q4 2022 and held it in 6 quarters.
  • Stifel Financial's Verrica Pharmaceuticals position peaked at $150K in Q4 2023.
  • 81 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q4 2024.

Based on Stifel Financial's 13F filing for Q4 2024, filed 13 Feb 2025.